Patient P-01891

Synthetic patientNBL-101 · Day 97 · 65–74 · M · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Stable

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

88%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 53 SC-12 recommended — Supportive Compound SC-12
Day 54 Patient accepted — Started SC-12 in the companion
Day 60 GI symptom burden −21% vs expected — Supportive Compound SC-12
Day 66 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

GI instability-11
Inflammatory activity-8
Nutritional resilience+6
Treatment adherence-2
Toxicity+2

What helped?

Supportive Compound SC-12Day 53
Result: symptom burden −21%

LIFE OS recommendation

GI Support Protocol GI-04

91%

probability of meaningful tolerance improvement

284 similar trajectories
84% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 57 and rising
- WearableSleep 5.9 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 31/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 54
Autonomic recovery ↑65
- WearableResting HR 73 bpm
- Wearable2,957 steps/day
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 48

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.1 · butyrate capacity 31/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 5.5 h
Steps: 3,202
Resting HR: 74 bpm

Daily log: GI score 57, nutritional resilience 44, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01494	65%	S14	GI-04	improved	42
P-01675	61%	S14	NP-02	improved	38
P-01598	53%	S14	GI-04	no change	45
P-01732	51%	S14	ME-01	improved	45
P-01777	51%	S14	SC-12	improved	43
P-01782	51%	S14	NP-02	no change	48
P-01413	50%	S14	GI-04	improved	44
P-01360	49%	S14	GI-04	improved	52
P-01488	48%	S12	GI-04	improved	50
P-01834	48%	S14	NP-02	improved	44
P-01328	47%	S14	SC-12	no change	49
P-01436	47%	S14	GI-04	improved	38